{"fetched":"2026-10-21","previousFetched":"2026-10-14","window":{"from":"2026-06-23","to":"2026-10-21"},"sources":{"drugsfda":"https://api.fda.gov/drug/drugsfda.json"},"approvals":[{"date":"2026-10-16","title":"KEYTRUDA QLEX (PEMBROLIZUMAB AND BERAHYALURONIDASE ALFA-PMPH): Efficacy","url":"https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761467","summary":"MERCK SHARP DOHME · SUPPL 8 · Efficacy","drugIds":["pembrolizumab"],"indicationIds":[],"firstSeen":"2026-10-21"},{"date":"2026-10-16","title":"KEYTRUDA (PEMBROLIZUMAB): Efficacy","url":"https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125514","summary":"MERCK SHARP DOHME · SUPPL 191 · Efficacy","drugIds":["pembrolizumab"],"indicationIds":[],"firstSeen":"2026-10-21"},{"date":"2026-09-29","title":"RIABNI (RITUXIMAB-ARRX): Bioequivalence","url":"https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761140","summary":"AMGEN INC · SUPPL 5 · Bioequivalence","drugIds":["rituximab"],"indicationIds":[],"firstSeen":"2026-10-21"},{"date":"2026-09-28","title":"RUXIENCE (RITUXIMAB-PVVR): SUPPL","url":"https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761103","summary":"PFIZER INC · SUPPL 20 · SUPPL","drugIds":["rituximab"],"indicationIds":[],"firstSeen":"2026-10-21"},{"date":"2026-09-25","title":"CAPECITABINE (CAPECITABINE): Labeling","url":"https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=090943","summary":"RISING · SUPPL 16 · Labeling","drugIds":["capecitabine"],"indicationIds":[],"firstSeen":"2026-10-21"},{"date":"2026-09-21","title":"EVEROLIMUS (EVEROLIMUS): ORIG","url":"https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=220597","summary":"NOVITIUM PHARMA · ORIG 1 · ORIG","drugIds":["everolimus"],"indicationIds":[],"firstSeen":"2026-10-21"},{"date":"2026-09-16","title":"ZORTRESS (EVEROLIMUS): Labeling","url":"https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021560","summary":"NOVARTIS · SUPPL 34 · Labeling","drugIds":["everolimus"],"indicationIds":[],"firstSeen":"2026-10-21"},{"date":"2026-09-14","title":"BEXLUTRY (LUTETIUM LU-177 DOTATATE): Type 5 - New Formulation or New Manufacturer","url":"https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=218525","summary":"CURIUM · ORIG 1 · Type 5 - New Formulation or New Manufacturer","drugIds":["lu-177-dotatate-generic"],"indicationIds":[],"firstSeen":"2026-10-21"},{"date":"2026-09-11","title":"PIXCLARA (FLORETYROSINE F-18): Type 1 - New Molecular Entity","url":"https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=218592","summary":"TELIX · ORIG 1 · Type 1 - New Molecular Entity","drugIds":["f-18-fet"],"indicationIds":[],"firstSeen":"2026-10-21"},{"date":"2026-09-03","title":"OMCAZIO (CABOZANTINIB LAURYLSULFATE): Type 5 - New Formulation or New Manufacturer","url":"https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=220613","summary":"HANDA ONCOL · ORIG 1 · Type 5 - New Formulation or New Manufacturer","drugIds":["cabozantinib"],"indicationIds":[],"firstSeen":"2026-10-21"},{"date":"2026-08-31","title":"FLUDEOXYGLUCOSE F18 (FLUDEOXYGLUCOSE F 18): Manufacturing (CMC)","url":"https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=079086","summary":"PETNET · SUPPL 31 · Manufacturing (CMC)","drugIds":["fludeoxyglucose-f18","f-18-fdg-brain"],"indicationIds":[],"firstSeen":"2026-10-21"},{"date":"2026-08-31","title":"IMFINZI (DURVALUMAB): Labeling","url":"https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761069","summary":"ASTRAZENECA UK LTD · SUPPL 60 · Labeling","drugIds":["durvalumab"],"indicationIds":[],"firstSeen":"2026-10-21"},{"date":"2026-08-14","title":"CABOZANTINIB S-MALATE (CABOZANTINIB S-MALATE): ORIG","url":"https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=213878","summary":"MSN · ORIG 1 · ORIG","drugIds":["cabozantinib"],"indicationIds":[],"firstSeen":"2026-10-21"},{"date":"2026-08-13","title":"TAUKLARIFY (FLORQUINITAU F-18): Type 1 - New Molecular Entity","url":"https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=220496","summary":"CERVEAU LANTHEUS · ORIG 1 · Type 1 - New Molecular Entity","drugIds":["f-18-florquinitau"],"indicationIds":[],"firstSeen":"2026-10-21"},{"date":"2026-07-31","title":"ZIMRIXBY (RITUXIMAB-CDXX): ORIG","url":"https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761376","summary":"DR REDDYS LABS SA · ORIG 1 · ORIG","drugIds":["rituximab"],"indicationIds":[],"firstSeen":"2026-10-21"},{"date":"2026-07-31","title":"PLUVICTO (LUTETIUM LU 177 VIPIVOTIDE TETRAXETAN): Efficacy","url":"https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=215833","summary":"NOVARTIS · SUPPL 37 · Efficacy","drugIds":["pluvicto"],"indicationIds":[],"firstSeen":"2026-10-21"},{"date":"2026-07-31","title":"KEYTRUDA QLEX (PEMBROLIZUMAB AND BERAHYALURONIDASE ALFA-PMPH): Labeling","url":"https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761467","summary":"MERCK SHARP DOHME · SUPPL 15 · Labeling","drugIds":["pembrolizumab"],"indicationIds":[],"firstSeen":"2026-10-21"},{"date":"2026-07-24","title":"XTANDI (ENZALUTAMIDE): Efficacy","url":"https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=203415","summary":"ASTELLAS · SUPPL 26 · Efficacy","drugIds":["enzalutamide"],"indicationIds":[],"firstSeen":"2026-10-21"},{"date":"2026-07-24","title":"XTANDI (ENZALUTAMIDE): Efficacy","url":"https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=213674","summary":"ASTELLAS · SUPPL 16 · Efficacy","drugIds":["enzalutamide"],"indicationIds":[],"firstSeen":"2026-10-21"},{"date":"2026-07-22","title":"NEURACEQ (FLORBETABEN F 18): Labeling","url":"https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=204677","summary":"LANTHEUS · SUPPL 41 · Labeling","drugIds":["f-18-florbetaben"],"indicationIds":[],"firstSeen":"2026-10-21"},{"date":"2026-07-10","title":"KEYTRUDA QLEX (PEMBROLIZUMAB AND BERAHYALURONIDASE ALFA-PMPH): Efficacy","url":"https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761467","summary":"MERCK SHARP DOHME · SUPPL 12 · Efficacy","drugIds":["pembrolizumab"],"indicationIds":[],"firstSeen":"2026-10-21"},{"date":"2026-07-10","title":"KEYTRUDA (PEMBROLIZUMAB): Efficacy","url":"https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125514","summary":"MERCK SHARP DOHME · SUPPL 194 · Efficacy","drugIds":["pembrolizumab"],"indicationIds":[],"firstSeen":"2026-10-21"},{"date":"2026-07-01","title":"CAPECITABINE (CAPECITABINE): Labeling","url":"https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=210203","summary":"HETERO LABS LTD V · SUPPL 7 · Labeling","drugIds":["capecitabine"],"indicationIds":[],"firstSeen":"2026-10-21"},{"date":"2026-07-01","title":"CAPECITABINE (CAPECITABINE): Labeling","url":"https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=211724","summary":"SOMERSET THERAPS LLC · SUPPL 6 · Labeling","drugIds":["capecitabine"],"indicationIds":[],"firstSeen":"2026-10-21"},{"date":"2026-06-30","title":"EVEROLIMUS (EVEROLIMUS): ORIG","url":"https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=219464","summary":"PHARMAZONE · ORIG 1 · ORIG","drugIds":["everolimus"],"indicationIds":[],"firstSeen":"2026-10-21"},{"date":"2026-06-29","title":"TRUXIMA (RITUXIMAB-ABBS): Bioequivalence","url":"https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761088","summary":"CELLTRION INC · SUPPL 35 · Bioequivalence","drugIds":["rituximab"],"indicationIds":[],"firstSeen":"2026-10-21"},{"date":"2026-06-24","title":"KEYTRUDA QLEX (PEMBROLIZUMAB AND BERAHYALURONIDASE ALFA-PMPH): Efficacy","url":"https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761467","summary":"MERCK SHARP DOHME · SUPPL 4 · Efficacy","drugIds":["pembrolizumab"],"indicationIds":[],"firstSeen":"2026-10-21"},{"date":"2026-06-24","title":"KEYTRUDA (PEMBROLIZUMAB): Efficacy","url":"https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125514","summary":"MERCK SHARP DOHME · SUPPL 187 · Efficacy","drugIds":["pembrolizumab"],"indicationIds":[],"firstSeen":"2026-10-21"}],"drugsfda":[{"applicationNumber":"BLA761467","sponsor":"MERCK SHARP DOHME","brand":"KEYTRUDA QLEX","generic":"PEMBROLIZUMAB AND BERAHYALURONIDASE ALFA-PMPH","submissionType":"SUPPL","submissionNumber":"8","classCode":"EFFICACY","classDescription":"Efficacy","statusDate":"2026-10-16","drugIds":["pembrolizumab"],"firstSeen":"2026-10-21"},{"applicationNumber":"BLA125514","sponsor":"MERCK SHARP DOHME","brand":"KEYTRUDA","generic":"PEMBROLIZUMAB","submissionType":"SUPPL","submissionNumber":"191","classCode":"EFFICACY","classDescription":"Efficacy","statusDate":"2026-10-16","drugIds":["pembrolizumab"],"firstSeen":"2026-10-21"},{"applicationNumber":"BLA761140","sponsor":"AMGEN INC","brand":"RIABNI","generic":"RITUXIMAB-ARRX","submissionType":"SUPPL","submissionNumber":"5","classCode":"BIOEQUIV","classDescription":"Bioequivalence","statusDate":"2026-09-29","drugIds":["rituximab"],"firstSeen":"2026-10-07"},{"applicationNumber":"BLA761103","sponsor":"PFIZER INC","brand":"RUXIENCE","generic":"RITUXIMAB-PVVR","submissionType":"SUPPL","submissionNumber":"20","classCode":"BIOSIMILAR","statusDate":"2026-09-28","drugIds":["rituximab"],"firstSeen":"2026-10-07"},{"applicationNumber":"ANDA090943","sponsor":"RISING","brand":"CAPECITABINE","generic":"CAPECITABINE","submissionType":"SUPPL","submissionNumber":"16","classCode":"LABELING","classDescription":"Labeling","statusDate":"2026-09-25","drugIds":["capecitabine"],"firstSeen":"2026-10-07"},{"applicationNumber":"ANDA220597","sponsor":"NOVITIUM PHARMA","brand":"EVEROLIMUS","generic":"EVEROLIMUS","submissionType":"ORIG","submissionNumber":"1","classCode":"UNKNOWN","statusDate":"2026-09-21","drugIds":["everolimus"],"firstSeen":"2026-09-30"},{"applicationNumber":"NDA021560","sponsor":"NOVARTIS","brand":"ZORTRESS","generic":"EVEROLIMUS","submissionType":"SUPPL","submissionNumber":"34","classCode":"LABELING","classDescription":"Labeling","statusDate":"2026-09-16","drugIds":["everolimus"],"firstSeen":"2026-09-23"},{"applicationNumber":"NDA218525","sponsor":"CURIUM","brand":"BEXLUTRY","generic":"LUTETIUM LU-177 DOTATATE","submissionType":"ORIG","submissionNumber":"1","classCode":"TYPE 5","classDescription":"Type 5 - New Formulation or New Manufacturer","statusDate":"2026-09-14","drugIds":["lu-177-dotatate-generic"],"firstSeen":"2026-09-23"},{"applicationNumber":"NDA218592","sponsor":"TELIX","brand":"PIXCLARA","generic":"FLORETYROSINE F-18","submissionType":"ORIG","submissionNumber":"1","classCode":"TYPE 1","classDescription":"Type 1 - New Molecular Entity","statusDate":"2026-09-11","drugIds":["f-18-fet"],"firstSeen":"2026-09-22"},{"applicationNumber":"NDA220613","sponsor":"HANDA ONCOL","brand":"OMCAZIO","generic":"CABOZANTINIB LAURYLSULFATE","submissionType":"ORIG","submissionNumber":"1","classCode":"TYPE 5","classDescription":"Type 5 - New Formulation or New Manufacturer","statusDate":"2026-09-03","drugIds":["cabozantinib"],"firstSeen":"2026-09-22"},{"applicationNumber":"ANDA079086","sponsor":"PETNET","brand":"FLUDEOXYGLUCOSE F18","generic":"FLUDEOXYGLUCOSE F 18","submissionType":"SUPPL","submissionNumber":"31","classCode":"MANUF (CMC)","classDescription":"Manufacturing (CMC)","statusDate":"2026-08-31","drugIds":["fludeoxyglucose-f18","f-18-fdg-brain"],"firstSeen":"2026-09-22"},{"applicationNumber":"BLA761069","sponsor":"ASTRAZENECA UK LTD","brand":"IMFINZI","generic":"DURVALUMAB","submissionType":"SUPPL","submissionNumber":"60","classCode":"LABELING","classDescription":"Labeling","statusDate":"2026-08-31","drugIds":["durvalumab"],"firstSeen":"2026-09-22"},{"applicationNumber":"ANDA213878","sponsor":"MSN","brand":"CABOZANTINIB S-MALATE","generic":"CABOZANTINIB S-MALATE","submissionType":"ORIG","submissionNumber":"1","classCode":"UNKNOWN","statusDate":"2026-08-14","drugIds":["cabozantinib"],"firstSeen":"2026-09-22"},{"applicationNumber":"NDA220496","sponsor":"CERVEAU LANTHEUS","brand":"TAUKLARIFY","generic":"FLORQUINITAU F-18","submissionType":"ORIG","submissionNumber":"1","classCode":"TYPE 1","classDescription":"Type 1 - New Molecular Entity","statusDate":"2026-08-13","drugIds":["f-18-florquinitau"],"firstSeen":"2026-10-07"},{"applicationNumber":"BLA761376","sponsor":"DR REDDYS LABS SA","brand":"ZIMRIXBY","generic":"RITUXIMAB-CDXX","submissionType":"ORIG","submissionNumber":"1","classCode":"UNKNOWN","statusDate":"2026-07-31","drugIds":["rituximab"],"firstSeen":"2026-09-22"},{"applicationNumber":"NDA215833","sponsor":"NOVARTIS","brand":"PLUVICTO","generic":"LUTETIUM LU 177 VIPIVOTIDE TETRAXETAN","submissionType":"SUPPL","submissionNumber":"37","classCode":"EFFICACY","classDescription":"Efficacy","statusDate":"2026-07-31","drugIds":["pluvicto"],"firstSeen":"2026-09-22"},{"applicationNumber":"BLA761467","sponsor":"MERCK SHARP DOHME","brand":"KEYTRUDA QLEX","generic":"PEMBROLIZUMAB AND BERAHYALURONIDASE ALFA-PMPH","submissionType":"SUPPL","submissionNumber":"15","classCode":"LABELING","classDescription":"Labeling","statusDate":"2026-07-31","drugIds":["pembrolizumab"],"firstSeen":"2026-09-22"},{"applicationNumber":"NDA203415","sponsor":"ASTELLAS","brand":"XTANDI","generic":"ENZALUTAMIDE","submissionType":"SUPPL","submissionNumber":"26","classCode":"EFFICACY","classDescription":"Efficacy","statusDate":"2026-07-24","drugIds":["enzalutamide"],"firstSeen":"2026-09-22"},{"applicationNumber":"NDA213674","sponsor":"ASTELLAS","brand":"XTANDI","generic":"ENZALUTAMIDE","submissionType":"SUPPL","submissionNumber":"16","classCode":"EFFICACY","classDescription":"Efficacy","statusDate":"2026-07-24","drugIds":["enzalutamide"],"firstSeen":"2026-09-22"},{"applicationNumber":"NDA204677","sponsor":"LANTHEUS","brand":"NEURACEQ","generic":"FLORBETABEN F 18","submissionType":"SUPPL","submissionNumber":"41","classCode":"LABELING","classDescription":"Labeling","statusDate":"2026-07-22","drugIds":["f-18-florbetaben"],"firstSeen":"2026-09-22"},{"applicationNumber":"BLA761467","sponsor":"MERCK SHARP DOHME","brand":"KEYTRUDA QLEX","generic":"PEMBROLIZUMAB AND BERAHYALURONIDASE ALFA-PMPH","submissionType":"SUPPL","submissionNumber":"12","classCode":"EFFICACY","classDescription":"Efficacy","statusDate":"2026-07-10","drugIds":["pembrolizumab"],"firstSeen":"2026-09-22"},{"applicationNumber":"BLA125514","sponsor":"MERCK SHARP DOHME","brand":"KEYTRUDA","generic":"PEMBROLIZUMAB","submissionType":"SUPPL","submissionNumber":"194","classCode":"EFFICACY","classDescription":"Efficacy","statusDate":"2026-07-10","drugIds":["pembrolizumab"],"firstSeen":"2026-09-22"},{"applicationNumber":"ANDA210203","sponsor":"HETERO LABS LTD V","brand":"CAPECITABINE","generic":"CAPECITABINE","submissionType":"SUPPL","submissionNumber":"7","classCode":"LABELING","classDescription":"Labeling","statusDate":"2026-07-01","drugIds":["capecitabine"],"firstSeen":"2026-09-22"},{"applicationNumber":"ANDA211724","sponsor":"SOMERSET THERAPS LLC","brand":"CAPECITABINE","generic":"CAPECITABINE","submissionType":"SUPPL","submissionNumber":"6","classCode":"LABELING","classDescription":"Labeling","statusDate":"2026-07-01","drugIds":["capecitabine"],"firstSeen":"2026-09-22"},{"applicationNumber":"ANDA219464","sponsor":"PHARMAZONE","brand":"EVEROLIMUS","generic":"EVEROLIMUS","submissionType":"ORIG","submissionNumber":"1","classCode":"UNKNOWN","statusDate":"2026-06-30","drugIds":["everolimus"],"firstSeen":"2026-09-22"},{"applicationNumber":"BLA761088","sponsor":"CELLTRION INC","brand":"TRUXIMA","generic":"RITUXIMAB-ABBS","submissionType":"SUPPL","submissionNumber":"35","classCode":"BIOEQUIV","classDescription":"Bioequivalence","statusDate":"2026-06-29","drugIds":["rituximab"],"firstSeen":"2026-09-22"},{"applicationNumber":"BLA761467","sponsor":"MERCK SHARP DOHME","brand":"KEYTRUDA QLEX","generic":"PEMBROLIZUMAB AND BERAHYALURONIDASE ALFA-PMPH","submissionType":"SUPPL","submissionNumber":"4","classCode":"EFFICACY","classDescription":"Efficacy","statusDate":"2026-06-24","drugIds":["pembrolizumab"],"firstSeen":"2026-09-22"},{"applicationNumber":"BLA125514","sponsor":"MERCK SHARP DOHME","brand":"KEYTRUDA","generic":"PEMBROLIZUMAB","submissionType":"SUPPL","submissionNumber":"187","classCode":"EFFICACY","classDescription":"Efficacy","statusDate":"2026-06-24","drugIds":["pembrolizumab"],"firstSeen":"2026-09-22"}],"notInCorpus":[{"date":"2026-09-21","title":"BRAVNETSA (LUTETIUM LU-177 DOTATATE)","url":"https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=217060","generic":"LUTETIUM LU-177 DOTATATE","why":"nuclide in the generic name","firstSeen":"2026-09-30"},{"date":"2026-07-24","title":"IDKIT:HP (CITRIC ACID ANHYDROUS AND 13C UREA)","url":"https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021314","generic":"CITRIC ACID ANHYDROUS AND 13C UREA","why":"nuclide in the generic name","firstSeen":"2026-09-22"}],"errors":[]}